228.74 USD
-0.16 (-0.07%)
228.95 USD
+0.21 (+0.09%)
Taking everything into account, SGEN scores 4 out of 10 in our fundamental rating. SGEN was compared to 525 industry peers in the Biotechnology industry. SGEN has a great financial health rating, but its profitability evaluates not so good. SGEN is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
- SGEN had negative earnings in the past year.
- SGEN had a negative operating cash flow in the past year.
1.2 Ratios
- The Return On Assets of SGEN (-20.64%) is better than 82.06% of its industry peers.
- The Return On Equity of SGEN (-29.41%) is better than 81.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| ROIC | N/A |
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 75.39%, SGEN belongs to the top of the industry, outperforming 84.88% of the companies in the same industry.
- In the last couple of years the Gross Margin of SGEN has declined.
- The Profit Margin and Operating Margin are not available for SGEN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
2. Health
2.1 Basic Checks
- SGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- SGEN has more shares outstanding than it did 1 year ago.
- There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 23.31 indicates that SGEN is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 23.31, SGEN belongs to the top of the industry, outperforming 94.68% of the companies in the same industry.
- There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 23.31 |
ROIC/WACCN/A
WACC10.94%
2.3 Liquidity
- SGEN has a Current Ratio of 2.67. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.67, SGEN is doing worse than 73.26% of the companies in the same industry.
- SGEN has a Quick Ratio of 2.12. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
- SGEN has a Quick ratio of 2.12. This is in the lower half of the industry: SGEN underperforms 76.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
- SGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.23%.
- SGEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.40%.
- Measured over the past years, SGEN shows a very strong growth in Revenue. The Revenue has been growing by 32.40% on average per year.
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%
3.2 Future
- Based on estimates for the next years, SGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 32.31% on average per year.
- SGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.49% yearly.
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SGEN. In the last year negative earnings were reported.
- Also next year SGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as SGEN's earnings are expected to grow with 29.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y29.83%
5. Dividend
5.1 Amount
- SGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SEAGEN INC / SGEN FAQ
What is the ChartMill fundamental rating of SEAGEN INC (SGEN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to SGEN.
What is the valuation status for SGEN stock?
ChartMill assigns a valuation rating of 1 / 10 to SEAGEN INC (SGEN). This can be considered as Overvalued.
What is the profitability of SGEN stock?
SEAGEN INC (SGEN) has a profitability rating of 2 / 10.
How financially healthy is SEAGEN INC?
The financial health rating of SEAGEN INC (SGEN) is 7 / 10.